

Advancing AI Drug Discovery in Clinical Trials at SMI's 3rd Annual AI in Drug Discovery Conference

SMi Group reports: Scientists to join 3rd Annual AI in Drug Discovery Conference to learn about the breakthroughs in clinical trials in ai drug discovery

LONDON, LONDON, UNITED KINGDOM, December 20, 2021 /EINPresswire.com/ -- SMI's 3rd Annual [AI in Drug Discovery Conference](#) welcomes attendees to join the two days of eye-opening key presentations on advancing ai drug discovery and to explore the opportunities of machine learning and AI in Drug Development.

The conference will be convening in London, UK on 14th and 15th March 2022.

Interested parties can register at <http://www.ai-indrugdiscovery.com/PR2>, register by 31stD January 2022 and save £100.

Drug discovery has always been challenging, more so today than ever before. While there has been success in addressing many diseases, others remain intractable. With this in mind the [two-day conference](#) will have targeted sessions covering new breakthroughs within clinical trials and the treatment of disease, these include:

Keynote Speaker - Natural language processing from clinical trials to patent mining

- Extended search and export capability for clinicaltrials.gov
 - Combining drug labels and patent claim extraction to interpret legal strategies
 - Examples of additional use cases within pharma
 - The future and possibilities of Natural Language processing
- Peter Henstock, Machine Learning & AI Technical Lead, Pfizer



How AI enhances every stage of Clinical Research

- Challenges in the current and traditional clinical trial process
- Overview of AI and its applications
- AI in Clinical trial – pros and cons
- Case studies
- Regulatory guidance and ethics within AI

Bhupathy Alagiriswamy, Clinical Trial Manager, Clinical Operations, Boehringer Ingelheim

Towards in silico clinical studies to predict drug efficacy

- Assessing the complexity of chronic diseases by combining comprehensive molecular profiling of patients with AI-modelling
- Using disease models to support various steps of drug development
- How far are we from performing virtual clinical studies to evaluate drug efficacy?

Philippe Moingeon, Head of therapeutic area immuno-inflammation, Application of AI to drug development, Servier Pharmaceuticals

Attendee joining us so far include leadXpro AG, DISCENGINE, CHARM Therapeutics and many more. Register and download the conference brochure here <http://www.ai-indrugdiscovery.com/PR2>

Proudly sponsored by [Optibrium](#)

For sponsorship enquiries contact Alia Malick, Director on +44 (0)20 7827 6168 or e-mail amalick@smi-online.co.uk

For media enquiries or a press pass contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6000 or email ssapal@smi-online.co.uk

SMi's 3rd Annual AI in Drug Discovery 2022

15 – 16 March 2022

London, UK

#SMiAIDrugDis

<http://www.ai-indrugdiscovery.com/PR2>

--- ENDS ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share

and Network. More information can be found at <http://www.smi-online.co.uk>

Mrs Simi Sapal
SMi Group
+44 2078276162
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/558814333>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.